Side by sideJohnson & Johnson (JNJ) and Gilead Sciences (GILD)Memos of October 14, 2026 and October 13, 2026
Johnson & Johnson vs Gilead Sciences stock: side by side (October 2026)
How do Johnson & Johnson and Gilead Sciences compare?
| Johnson & Johnson JNJ | Gilead Sciences GILD | |
|---|---|---|
| Revenue growth | 6.0%2025 | 2.4%2025 |
| Operating margin | 34.5%2025 | 34.0%2025 |
| Free cash flow | 19,536US$ millions · 2025 | 9,456US$ millions · 2025 |
| Free cash flow yield | 3.3%Today (Oct 14, 2026) | 5.1%Today (Oct 13, 2026) |
| Dividend yield | 2.2%Today (Oct 14, 2026) | 2.2%Today (Oct 13, 2026) |
| P/E, last 12 months | 37.7xToday (Oct 14, 2026) | not meaningfulToday (Oct 13, 2026) |
| P/E, next 12 months | 20.1xToday (Oct 14, 2026) | 15.1xToday (Oct 13, 2026) |
| Weighted price forecast, about 1 year | 229.07 (-6%)October 2027 | 124.65 (-15 %)October 2027 |
| Weighted price forecast, about 3 years | 251.90 (+8%)October 2029 | 141.61 (+1 %)October 2029 |
Read the full Johnson & Johnson memoRead the full Gilead Sciences memoYour first report is free · no card
Who leads on what?
| Leads | The lead is | |
|---|---|---|
| Revenue growth | Johnson & Johnson | The higher figure |
| Operating margin | Johnson & Johnson | The higher figure |
| Free cash flow | Johnson & Johnson | The higher figure |
| Free cash flow yield | Gilead Sciences | The higher figure |
| Dividend yield | — | The higher figure |
| P/E, last 12 months | — | The lower figure |
| P/E, next 12 months | Gilead Sciences | The lower figure |
| Weighted price forecast, about 1 year | Johnson & Johnson | The higher weighted return |
| Weighted price forecast, about 3 years | Johnson & Johnson | The higher weighted return |
What does each company do?
Johnson & Johnson sells prescription medicines and medical devices through Innovative Medicine and MedTech.
Johnson & Johnson (JNJ), from our memo of October 14, 2026 · Johnson & Johnson stock forecast
Gilead Sciences sells prescription medicines for HIV—a virus that attacks the immune system—liver disease, cancer and serious infections.
Gilead Sciences (GILD), from our memo of October 13, 2026 · Gilead Sciences stock forecast
Read the full Johnson & Johnson memoRead the full Gilead Sciences memoYour first report is free · no card
More on Johnson & Johnson
More on Gilead Sciences
Side by side
Lilly vs Johnson & JohnsonJohnson & Johnson vs MerckJohnson & Johnson vs AmgenJohnson & Johnson vs Abbott